Latest Manufacturing News

Eureka Group Holdings has acquired Nagambie Lifestyle Park for $11 million, marking its ninth all-age rental community and reinforcing its affordable housing strategy in regional Victoria.

MyEco Group has reported a record quarter for its MyEcoBag® products, driven by strong Australian retail growth and poised to benefit from upcoming NSW organic waste regulations.

Atomo Diagnostics has landed a significant $502,000 order for HIV self-tests destined for an African country, underscoring sustained demand for accessible diagnostics in the region.

Amaero Ltd has lowered its FY2026 revenue guidance due to delayed U.S. government contracts but reports strong contracted revenue and a robust cash position heading into 2026.

Aquirian Limited reports a robust first half of FY26 with revenue up 27.4% and EBITDA more than doubling, driven by strategic facility upgrades and promising joint ventures.

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.

Little Green Pharma Ltd has agreed to acquire Cannatrek Ltd in a transformational merger that will create a leading vertically integrated medicinal cannabis group across Australia and Europe. The deal combines cultivation, manufacturing, distribution, clinics, and digital health platforms under one roof, positioning the combined entity for accelerated growth.

HighCom Limited appoints seasoned executive Geoffrey Knox as Executive Chairman and CEO, signaling a strategic push to strengthen its defence manufacturing and sustainment operations in Australia and the US.

Southern Cross Gold Consolidated Ltd throws its weight behind Australia’s new A$1.2 billion Critical Minerals Strategic Reserve, spotlighting its Sunday Creek gold-antimony project as a key player in securing domestic supply and reducing reliance on China.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

NeuroScientific Biopharmaceuticals reports encouraging clinical responses in fistulising Crohn’s disease patients treated under Australia’s Special Access Scheme, setting the stage for pivotal Phase 2 trials later this year.

RareX Limited has achieved a major regulatory milestone with the granting of a Mining Lease for its Cummins Range Project in Western Australia, significantly reducing development risk and paving the way for focused metallurgical optimisation and mine planning.